Common side effects (may affect up to 1 in 10 people):
Rare side effects (may affect up to 1 in 1,000 people):
Very rare side effects (may affect up to 1 in 10,000 people):
Unknown side effects (frequency cannot be estimated from available data):
The class of medications to which Quetiapine MABO belongs may cause heart rhythm problems that can be severe and, in severe cases, be fatal.
Some side effects are only observed when a blood test is performed. These include changes in the amount of certain fats (triglycerides and total cholesterol) or sugar in the blood, changes in the amount of thyroid hormones in the blood, increased liver enzymes, decreased numbers of certain types of blood cells, decreased red blood cell count, increased creatine-phosphocinase in the blood (a substance found in muscles), decreased sodium levels in the blood, and increased levels of prolactin hormone in the blood. Elevated levels of prolactin hormone may, in rare cases, lead to:
Your doctor may ask you to have blood tests from time to time.
Side effects in children and adolescents
The same side effects that may occur in adults may also occur in children and adolescents.
The following side effects have been observed more frequentlyin children and adolescents or have not been observed in adults:
Very common side effects (may affect more than 1 in 10 people):
Common side effects (may affect up to 1 in 10 people):
Reporting side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:https//www.notificaram.es.
Byreportingsideeffects,youcancontributetoprovidingmoreinformationonthesafetyofthismedication.
Keep this medication out of the sight and reach of children.
Store in the original packaging to protect it from moisture.
This medication does not require any special storage temperature.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Medications should not be disposed of through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection pointat the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of Quetiapina MABO
Appearance of Quetiapina MABO prolonged-release tablets and contents of the packaging
The tablets are yellow, oblong, biconvex, film-coated and have “Q 200” engraved on one side.
They are presented in aluminumPVC/PVDC blisters, in packs of 60 tablets.
Marketing Authorization Holder
MABO-FARMA, S.A.
Calle Vía de los Poblados, 3, Edificio 6
28033 Madrid,
Spain.
Responsible for manufacturing
Merckle GmbH
Ludwig-Merckle Strasse 3
D-89143 Blaubeuren-Weiler
Germany
or
Teva UK
Brampton Road, HampdenPark, Eastbourne, East Sussex, BN22 9AG
United Kingdom
Last review date of the leaflet: June 2024
The detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.